Comparison of ticagrelor and clopidogrel in patients with acute coronary syndrome at high bleeding or ischemic risk
Çalık, Ali Nazmi
Tanboğa, İbrahim Halil
MetadataShow full item record
CitationAkyuz, S., Calik, A. N., Yaylak, B., Onuk, T., Eren, S., Kolak, Z., Mollaalioglu, F., Durak, F., Cetin, M., & Tanboga, I. H. (2023). Comparison of Ticagrelor and Clopidogrel in Patients with Acute Coronary Syndrome at High Bleeding or Ischemic Risk. The American journal of cardiology, S0002-9149(23)01198-0. Advance online publication. https://doi.org/10.1016/j.amjcard.2023.10.046
Current guidelines recommend individualizing the choice and duration of P2Y12 inhibitor therapy based on the trade-off between bleeding and ischemic risk. However, whether a potent P2Y12 inhibitor (ticagrelor) or a less potent one (clopidogrel) is more appropriate in patients with acute coronary syndrome (ACS) in the setting of high bleeding or ischemic risk is not clear. The aim of this study is to compare the clinical outcomes of clopidogrel and ticagrelor in patients with ACS at high bleeding or ischemic risk. A total of 5713 patients with ACS were included in this retrospective study. The Cox proportional hazard regression model were adjusted applying the inverse probability weighted (IPW) approach to reduce treatment selection bias. The primary clinical outcome was all-cause death. Secondary outcomes included in-hospital death, ACS, target vessel revascularization, stent thrombosis, stroke, or clinically significant or major bleeding. The median follow-up duration was 53.6 months. After multivariable Cox model using IPW, all-cause death in the overall population and subgroups of patients at high bleeding risk, and/or at high ischemic risk were not significantly different between clopidogrel and ticagrelor. Rates for secondary outcomes were also similar between the groups. In conclusion, ticagrelor and clopidogrel are associated with comparable clinical outcomes among patients with ACS irrespective of bleeding and ischemic risk.